Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma

Table 1 Inclusion and exclusion criteria of the enrolled patients

Eligibility criteria	Exclusion criteria
Histopathology confirmed	MRI examination contraindication
Non-invasive diagnosis criteria [(EASL) 2012]1	Significant renal insufficiency
Cirrhotic patients
Hypervascular in the arterial phase
Washout in the portal venous or delayed phase
Non-antineoplaston therapy	Severe motion artifacts on MRI images
The largest diameter of lesion ≥ 2 cm	Hepatic vein/portal cancer embolus
Age of patients ≥ 18 yr	Inferior vena cava embolus
	Inability of informed written consent

¹European Association for the Study of the Liver suggested non-invasive diagnosis criteria on 4-phase multidetector CT scan[13]. EASL: European Association for the Study of the Liver; MRI: Magnetic resonance imaging.